Zacks Investment Research upgraded shares of Vernalis (OTCMKTS:VNLPY) from a hold rating to a buy rating in a research note released on Friday. The firm currently has $0.25 target price on the stock.

According to Zacks, “Vernalis Group plc is a research and development-stage pharmaceutical company based in Oxford, UK, which is developing drugs for the treatment of unmet medical needs such as cancer and inflammatory and infectious diseases. The main technology platform is inhibition of metalloenzymes which will be supplemented through the addition of externally-generated programs. “

Vernalis (VNLPY) opened at $0.26 on Friday. Vernalis has a 52-week low of $0.26 and a 52-week high of $0.61.

TRADEMARK VIOLATION NOTICE: “Vernalis (VNLPY) Raised to Buy at Zacks Investment Research” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/25/vernalis-vnlpy-raised-to-buy-at-zacks-investment-research.html.

About Vernalis

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Get a free copy of the Zacks research report on Vernalis (VNLPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with MarketBeat.com's FREE daily email newsletter.